Top Gainers: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), XG Technology (NASDAQ:XGTI), Neurometrix (NASDAQ:NURO), CorMedix (NYSEMKT:CRMD), Doral Financial (NYSE:DRL)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) surged 40 percent after a study said a combination of two of the company’s drugs shows promise for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock performance was 40.41% in last session and finished the day at $93.53. Traded volume was 25.24million shares in the last session and the average volume of the stock remained 1.58million shares. The beta of the stock remained 0.38. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) insider ownership is 0.20%.

XG Technology Inc (NASDAQ:XGTI) climbed nearly 40 percent today after the company reported that it has been given a subcontractor position on $497 million contract to offer communications and network services to the United States Army. XG Technology Inc (NASDAQ:XGTI) rose 24.86 percent to $2.31 Tuesday on volume of 13.66million shares. The intra-day range of the stock was $2.25 to $3.01. XG Technology Inc (NASDAQ:XGTI) has a market capitalization of $44.63million.

NeuroMetrix Inc. (NASDAQ:NURO) an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain nerve diseases and sleep disorders today reported the receipt of marketing certification from Technischer Überwachungs-Verein SÜD Japan Ltd. (TÜV SÜD Japan) for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health Labor and Welfare. Neurometrix Inc (NASDAQ:NURO)’s stock on June 24, 2014 reported a increase of 19.14% to the closing price of $2.24. Its fifty two weeks range is $1.47 -$4.25. The total market capitalization recorded $13.32million. The overall volume in the last trading session was 3.30million shares. In its share capital, NURO has 5.93million outstanding shares.

CorMedix Inc. (AMEX:CRMD) announced the progress of on-going discussions with the U.S. Food and Drug Administration for a planned pivotal Phase 3 randomized controlled trial (“RCT”) for Neutrolin® for use in hemodialysis patients with a central venous catheter. CorMedix Inc. (AMEX:CRMD) worked with the FDA to develop the protocol design for the planned trial for a marketing application. Based on FDA input, the planned Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe. Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program. On Tuesday, shares of CorMedix Inc. (NYSEMKT:CRMD) advanced 28.86% to close the day at $1.92. Company monthly performance is recorded as 46.56%. CorMedix Inc. (NYSEMKT:CRMD) quarterly revenue growth is -27.00%.

Doral Financial Corp. (NYSE:DRL) opted to file papers on June 18, appealing against a decision taken by Puerto Rico’s Court Of First Instance and asked the Honorable Puerto Rico Supreme Court to righteously assume jurisdiction of DRL’s appeal. Doral Financial Corp. (NYSE:DRL) stock performance was 5.03% in last session and finished the day at $4.59. Traded volume was 811,609.00million shares in the last session and the average volume of the stock remained 977.32K shares. The beta of the stock remained 2.67. Doral Financial Corp. (NYSE:DRL) insider ownership is 4.12%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone